Molsidomine

Molsidomine, a nitric oxide (NO) donor, is an orally active vasodilator agent. Molsidomine is a prodrug that can be rapidly metabolized in the liver to its active metabolite, Linsidomine (HY-101200). Molsidomine can be used for the study of angina pectoris, mental disorders and diabetic complications^[1][2]. In Vivo:Molsidomine (2-4 mg/kg; intraperitoneal injection; single dose) in a rat schizophrenia-like model induced by Apomorphine (HY-12723) alleviates the spatial recognition and emotional memory impairments caused by Apomorphine^[1].
Molsidomine (1 mg/kg; intraperitoneal injection; single dose) combined with either Clozapine (HY-14539) (0.1 mg/kg; intraperitoneal injection; single dose) or Risperidone (HY-11018) (0.03 mg/kg; intraperitoneal injection; single dose) counteracts the non-spatial recognition memory impairments induced by Apomorphine in rats^[1].
Molsidomine (5-10 mg/kg; oral administration; once a day; for 8 weeks) in a Wistar rat model of diabetic neuropathy induced by Streptozotocin (HY-13753) improves the motor coordination, mechanical allodynia, and mechanical hyperalgesia caused by diabetes, increases the nerve conduction velocity, reduces the glycosylated hemoglobin and malondialdehyde levels, increases the content of reduced glutathione in the sciatic nerve, and improves the cellular structure of the sciatic nerve^[2].